Pikralida sp. z o.o. is implementing a project, co-financed from the European Funds, entitled “Establishment of a R&D Laboratory of Super Generic Drugs”.
Project no. RPWP.01.02.00-30-0047/19-00 is implemented under the Regional Operational Programme for Wielkopolskie Voivodeship 2014-2020; Priority Axis I: Innovative and Competitive Economy, Measure 1.2 Strengthening innovation potential of enterprises in of the Wielkopolskie Voivodeship.
The aim of the Project is to obtain a prototype formulation of a pharmaceutical form of a tablet containing an active ingredient in an amorphous form. Moreover, under the implementation of the Project, the Beneficiary is to develop a new service to extend its offer, namely the development of an amorphisation technology of active ingredients based on hot extrusion as well as the development of drug formulations containing an amorphous form of an active ingredient, while enhancing the service of the development of analytical methods.
- Project budget: PLN 1 972 710,00
- EU funding for the Project: PLN 1,260,200.00
- Duration of the Project: 01/10/2019 – 30/06/2021
Co-funded projects:
-
Project no. POIR.01.01.01-00-0072/21
Development of an innovative pilot line and its validation under real conditions using synthesis process of a model active pharmaceutical ingredient.
-
Project no. POIR.01.01.01-00-0235/20
Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.
-
Project no. POIR.04.01.04-00-0063/20-00
Development of the innovative formulation of the combination drug dedicated for the geriatric patients in pain pharmacotherapy
-
Project no. TANGO-IV-C/0012/2019
Development of an innovative combined preparation dedicated for the treatment of hypertension.